(Q52042067)

20 April 2018

title

Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin 12 (IL-12) or other cytokines compared with exogenous IL-12. (English)

1 reference

20 April 2018

0 references

1 reference

3

Giovarelli M

1 reference

20 April 2018

Cavallo F

1

1 reference

20 April 2018

Signorelli P

2

1 reference

20 April 2018

Musiani P

4

1 reference

20 April 2018

Modesti A

5

1 reference

20 April 2018

Brunda MJ

6

1 reference

20 April 2018

Colombo MP

7

1 reference

20 April 2018

Forni G

8

1 reference

20 April 2018

language of work or name

English

0 references

publication date

1 July 1997

1 reference

20 April 2018

Journal of the National Cancer Institute

published in

1 reference

20 April 2018

volume

89

1 reference

20 April 2018

page(s)

1049-1058

1 reference

20 April 2018

issue

14

1 reference

20 April 2018

Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

The role of IL-12 in the induction of organ-specific autoimmune diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Antitumor and antimetastatic activity of interleukin 12 against murine tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Effect of interleukin 12 on tumor induction by 3-methylcholanthrene

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Gene therapy for cancer: what have we done and where are we going?

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

IP-10, a -C-X-C- chemokine, elicits a potent thymus-dependent antitumor response in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Cellular and molecular mechanisms underlying IL-12-induced tumor regression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Inhibition of angiogenesis in vivo by interleukin 12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Interferon gamma-independent effects of interleukin 12 administered during acute or established infection due to Leishmania major

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Regression of an established tumor genetically modified to release granulocyte colony-stimulating factor requires granulocyte-T cell cooperation and T cell-produced interferon gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Co-expression of B7-1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJNCI%2F89.14.1049

21 January 2018

Identifiers

DOI

10.1093/JNCI/89.14.1049

1 reference

20 April 2018

PubMed ID

9230887

1 reference

20 April 2018